Contineum Therapeutics (NASDAQ:CTNM – Get Free Report) and Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.
Risk and Volatility
Contineum Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Aardvark Therapeutics has a beta of 4.5, suggesting that its share price is 350% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Contineum Therapeutics and Aardvark Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Contineum Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Aardvark Therapeutics | 2 | 4 | 6 | 1 | 2.46 |
Profitability
This table compares Contineum Therapeutics and Aardvark Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Contineum Therapeutics | N/A | -27.09% | -25.64% |
| Aardvark Therapeutics | N/A | -61.71% | -56.29% |
Valuation and Earnings
This table compares Contineum Therapeutics and Aardvark Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Contineum Therapeutics | $50.00 million | 9.51 | -$59.98 million | ($1.95) | -6.52 |
| Aardvark Therapeutics | N/A | N/A | -$57.59 million | ($3.21) | -1.20 |
Aardvark Therapeutics has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Aardvark Therapeutics beats Contineum Therapeutics on 6 of the 11 factors compared between the two stocks.
About Contineum Therapeutics
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
About Aardvark Therapeutics
Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}
